NOVARTIS AG

ISIN: CH0012005267 WKN: 1200526 Asset Class: Stock



Company Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

	20	2023		2022		2021	
Financial figures		Liabilities and equity		Liabilities and equity		Liabilities and equity	
Current assets	25,654,333,000		34,149,132,000		41,655,955,000		
Common stock capital		694,361,000		823,428,000		820,946,000	
Fixed assets	61,729,135,000		78,507,846,000		82,154,750,000		
Equity capital of a company		39,347,137,000		54,978,159,000		61,796,015,000	
Cash and cash equivalents	11,272,218,000		6,954,728,000		11,304,638,000		
Accrued liabilities		2,802,694,000		3,079,065,000		4,279,671,000	
Other assets	-		-		-		
Current liabilities		22,211,143,000		26,512,531,000		27,524,019,000	
Prepayments and accrued income	-		-		-		
Non-current liabilities		25,825,188,000		31,166,287,000		34,490,672,000	
Different income		-		-		-	
Other liabilities		1,004,088,000		1,459,965,000		1,343,946,000	
Total assets	87,383,469,000	87,383,469,000	112,656,978,000	112,656,978,000	123,810,706,000	123,810,706,000	

Balance notes

	2023	2022	2021
Accounting standard	IFRS	IFRS	IFRS
Employees	76,057	101,703	104,323
Equity ratio	45.11%	48.87%	50.03%
Debt-equity ratio	121.69%	104.63%	99.86%

Others

	2023	2022	2021
Tax Expense Rate	6.03%	16.90%	19.62%

NOVARTIS AG

ISIN: CH0012005267 WKN: 1200526 Asset Class: Stock

Income statement			
	2023	2022	2021
Turnover	40,834,735,000	48,273,766,000	47,199,917,000
Net income	7,699,648,000	6,642,477,000	21,961,593,000
EBIT	8,598,306,693	8,799,226,463	10,845,852,815
Operating income before taxes	8,210,082,000	8,003,445,000	9,872,248,000
Cash Flow	12,992,707,000	13,596,306,000	13,778,909,000
Net interest income	-223,764,000	-627,477,000	-766,155,000
Research and development expenses	7,389,613,000	8,484,798,000	8,722,101,000
Income taxes	495,157,000	1,352,372,000	1,937,330,000
Result from investments in subsidaries, associates and other	-11,682,000	-8,595,000	14,023,932,000
Revenues per employee	547,366	483,910	461,263

Board of Directors	
200.000.000	
Charles Sawyers	Member of the administrative board
Nancy Andrews	Member of the administrative board
· · · · · · · · · · · · · · · · · · ·	Member of the administrative board
Simon Moroney	
Ana de Pro Gonzalo	Member of the administrative board
Bridgette Heller	Member of the administrative board
Daniel Hochstrasser	Member of the administrative board
Frans van Houten	Member of the administrative board
John Young	Member of the administrative board
Mary Doherty	Member of the administrative board
Patrice Bula	Member of the administrative board
Ton Büchner	Member of the administrative board
William Winters	Member of the administrative board
Hans Jörg Reinhardt	Chairman of the administrative boar

Members of Management Board			
Vasant (Vas) Narasimhan	Chairman of Managing Board		
Klaus Moosmayer	Member of Executive Committee		
Steffen Lang	Member of Executive Committee		
Aharon Gal	Member of Executive Committee		
Fiona H. Marshall	Member of Executive Committee		
Harry Kirsch	Member of Executive Committee		
Karen Hale	Member of Executive Committee		
Kees Roks	Member of Executive Committee		
Lutz Hegemann	Member of Executive Committee		
Michelle Weese	Member of Executive Committee		
Patrick Horber	Member of Executive Committee		
Rob Kowalski	Member of Executive Committee		
Shreeram Aradhye	Member of Executive Committee		
Victor Bulto	Member of Executive Committee		